Stoke Therapeutics, Inc. (STOK) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 27.59M USD | |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $27.59M | (m) | (m) |
| 2026-03-31 | (m) | $32.08M | (m) | (m) |
| 2025-12-31 | (m) | $184.42M | (m) | (m) |
| 2025-09-30 | (m) | $205.63M | (m) | (m) |
| 2025-06-30 | (m) | $199.89M | (m) | (m) |
| 2025-03-31 | (m) | $190.91M | (m) | (m) |
| 2024-12-31 | (m) | $36.55M | (m) | (m) |
| 2024-09-30 | (m) | $16.74M | (m) | (m) |
| 2024-06-30 | (m) | $15.16M | (m) | (m) |
| 2024-03-31 | (m) | $7.84M | (m) | (m) |
| 2023-12-31 | (m) | $8.78M | (m) | (m) |
| 2023-09-30 | (m) | $9.25M | (m) | (m) |
| 2023-06-30 | (m) | $8.84M | (m) | (m) |
| 2023-03-31 | (m) | $14.56M | (m) | (m) |
| 2022-12-31 | (m) | $12.40M | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |